Heart disease prediction by traditional risk factors as good as with an exhaustive genetic test

February 20, 2020 – Traditional cardiovascular risk factors often assessed in an annual physical, such as blood pressure, cholesterol levels, diabetes, and smoking status, may at least be as valuable in predicting who will develop coronary heart disease (CHD) as a sophisticated genetic test that surveys millions of different points in DNA, a study led by a UT Southwestern Medical Center researcher suggests. The findings of the study support the utility of these tried-and-true methods.

Some studies have explored the utility of DNA to predict risk more accurately. For example, in 2018, researchers published a  study in Nature Genetics that showed that variations among individuals at more than 6 million points in their DNA were accurately associated with who had already had a heart attack. However, it remained unclear whether this association with cardiac events that had already taken place could translate into predictive value for future events, as well as how this predictive value compared with calculations made using traditional risk factors.

To answer these questions, the research team from the UT Southwestern Medical Center used data from two long-running studies that follow heart health in thousands of volunteers: the Atherosclerosis Risk in Communities (ARIC) study and the Multi-Ethnic Study of Atherosclerosis (MESA). Because the polygenic risk calculator had been developed using individuals of European descent, the research team included only this population in their own analysis, extracting data on traditional CHD risk factors and genetics from 7,306 individuals ages 45-79. They ran this information through both the ACC/AHA tool and the polygenic risk calculator for these study volunteers at baseline, then checked how these scores compared with which individuals experienced cardiac events over an average of about 15 years.

Their results showed a strong association between polygenic risk scores and CHD, with those scoring highest on this calculator at baseline most likely to experience cardiac events over the follow-up period. However, these results were roughly the same using the ACC/AHA calculator. Although the polygenic risk calculator reclassified about 5% of individuals to a higher or lower risk category, many of these classifications didn’t match who developed CHD or not.

According to the research team, the bottom line is that the polygenic risk score didn’t add much information beyond the ACC/AHA score that could help doctors more accurately predict CHD risk.

The researchers suggest that genetics is an important determinant of familial diseases and a key tool for understanding human biology, and the idea that genetics may also be important for predicting common diseases has been a source of excitement over the past several years. But as an everyday clinical tool for predicting cardiovascular risk, human genetics isn’t there yet. Researchers and clinicians should not lose sight of traditional risk factors for assessing risk of cardiovascular disease, counseling about that risk, and strategizing on reducing it by continuing to also consider traditional cardiovascular risk factors.

Coronary heart disease is the leading cause of death worldwide, killing an estimated 3.8 million men and 3.4 million women each year.

See this sequence on risk factors for coronary heart disease (CHD):

Print Friendly, PDF & Email

Tags: , , , , , , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • How genetic variation gives rise to differences in mathematical ability October 22, 2020
    DNA variation in a gene called ROBO1 is associated with early anatomical differences in a brain region that plays a key role in quantity representation, potentially explaining how genetic variability might shape mathematical performance in children, according to a study published October 22nd in the open-access journal PLOS Biology by Michael Skeide of the Max […]
  • High-quality cat genome helps identify novel cause of dwarfism October 22, 2020
    A new and improved cat genome developed by the feline research teams at the University of Missouri and Texas A&M University has already proven to be a valuable tool for feline biomedical research by helping to confirm existing gene variants and new candidate genes underlying diseases in cats. The new findings are published October 22nd […]
  • Multiple sclerosis as the flip side of immune fitness October 22, 2020
    About half of the people with multiple sclerosis have the HLA-DR15 gene variant. A study led by the University of Zurich has now shown how this genetic predisposition contributes to the development of the autoimmune disease multiple sclerosis in combination with environmental factors. The decisive factor is the shaping of a repertoire of immune cells […]
  • Scientists use gene therapy and a novel light-sensing protein to restore vision in mice October 22, 2020
    A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of MCO1. The company is planning a U.S. clinical […]
  • Diagnostic, therapeutic advance for rare neurodegenerative disorder October 21, 2020
    Mayo Clinic researchers, along with national and global collaborators, have developed a potential test for Machado-Joseph disease, or spinocerebellar ataxia type 3 (SCA3)—a disease that has no cure. They also have clarified the role of a gene target associated with the disease.
Top